The American Journal of Medicine
Volume 119, Issue 3 , Pages 217-224 , March 2006

Smoking Increases the Treatment Failure for Helicobacter pylori Eradication

  • Takeshi Suzuki

      Affiliations

    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
    • Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Science
    • ,
  • Keitaro Matsuo

      Affiliations

    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
    • Corresponding Author InformationCorrespondence should be addressed to Keitaro Matsuo, MD, PhD, MSc, Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute 1-1 Kanokoden, Chikusa-ku Nagoya 464-8681, Japan Phone: +81-52-762-6111, Fax: +81-52-763-5233.
    • ,
  • Hidemi Ito

      Affiliations

    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
    • ,
  • Akira Sawaki

      Affiliations

    • Department of Gastroenterology, Aichi Cancer Center Central Hospital
    • ,
  • Kaoru Hirose

      Affiliations

    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
    • ,
  • Kenji Wakai

      Affiliations

    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
    • ,
  • Shigeki Sato

      Affiliations

    • Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Science
    • ,
  • Tsuneya Nakamura

      Affiliations

    • Department of Endoscopy, Aichi Cancer Center Central Hospital, Nagoya, Japan
    • ,
  • Kenji Yamao

      Affiliations

    • Department of Gastroenterology, Aichi Cancer Center Central Hospital
    • ,
  • Ryuzo Ueda

      Affiliations

    • Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Science
    • ,
  • Kazuo Tajima

      Affiliations

    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan

References 

  1. Marshall BJ , Warren JR . Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration . Lancet . 1984;1:1311–1315
  2. Wotherspoon AC , Ortiz-Hidalgo C , Falzon MR , Isaacson PG . Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma . Lancet . 1991;338:1175–1176
  3. Parsonnet J , Friedman GD , Vandersteen DP , et al.   Helicobacter pylori infection and the risk of gastric carcinoma . N Engl J Med . 1991;325:1127–1131
  4. Gisbert JP , Gonzalez L , Calvet X . Systematic review and meta-analysis (proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication) . Helicobacter . 2005;10:157–171
  5. Graham DY , Lew GM , Malaty HM , et al.   Factors influencing the eradication of Helicobacter pylori with triple therapy . Gastroenterology . 1992;102:493–496
  6. Lind T , Megraud F , Unge P , et al.   The MACH2 study (role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies) . Gastroenterology . 1999;116:248–253
  7. Broutet N , Tchamgoue S , Pereira E , et al.   Risk factors for failure of Helicobacter pylori therapy—results of an individual data analysis of 2751 patients . Aliment Pharmacol Ther . 2003;17:99–109
  8. Lin CK , Hsu PI , Lai KH , et al.   One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy . J Clin Gastroenterol . 2002;34:547–551
  9. van Doorn LJ , Schneeberger PM , Nouhan N , et al.   Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment . Gut . 2000;46:321–326
  10. Broutet N , Marais A , Lamouliatte H , et al.   cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia . J Clin Microbiol . 2001;39:1319–1322
  11. Moayyedi P , Chalmers DM , Axon AT . Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori . J Gastroenterol . 1997;32:24–27
  12. Kamada T , Haruma K , Komoto K , et al.   Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin . Helicobacter . 1999;4:204–210
  13. Maconi G , Parente F , Russo A , et al.   Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? . Am J Gastroenterol . 2001;96:359–366
  14. Perri F , Villani MR , Festa V , et al.   Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy’ . Aliment Pharmacol Ther . 2001;15:1023–1029
  15. Treiber G , Wittig J , Ammon S , et al.   Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication (a randomized controlled trial (MACLOR study)) . Arch Intern Med . 2002;162:153–160
  16. Lee SB , Park SJ , Ryu JK , et al.   Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype . Korean J Gastroenterol . 2003;42:468–475
  17. De Francesco V , Zullo A , Hassan C , et al.   The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme (a prospective, randomised study) . Dig Liver Dis . 2004;36:322–326
  18. Janssen MJ , Laheij RJ , Jansen JB , de Boer WA . The influence of pretreatment on cure rates of Helicobacter pylori eradication . Neth J Med . 2004;62:192–196
  19. Koivisto TT , Rautelin HI , Voutilainen ME , et al.   First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance (results of three eradication regimens) . Aliment Pharmacol Ther . 2005;21:773–782
  20. Manes G , Pieramico O , Perri F , et al.   Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy . Dig Dis Sci . 2005;50:443–448
  21. Bertoni G , Sassatelli R , Nigrisoli E , et al.   Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori (a controlled trial versus omeprazole plus amoxicillin) . Am J Gastroenterol . 1996;91:258–263
  22. DerSimonian R , Laird N . Meta-analysis in clinical trials. Prognostic role of antibody reactivity to melanoma . Control Clin Trials . 1986;7:177–188
  23. Thompson SG , Sharp SJ . Explaining heterogeneity in meta-analysis (a comparison of methods) . Stat Med . 1999;18:2693–2708
  24. Begg CB , Mazumdar M . Operating characteristics of a rank correlation test for publication bias . Biometrics . 1994;50:1088–1101
  25. Kirstein FW , Epple HJ , Bojarski C , et al.   Dual versus triple therapy (comparison of five antibiotic regimens for eradication of Helicobacter pylori in a prospective, randomized study) . Z Gastroenterol . 1998;36:803–809
  26. Cutler AF , Schubert TT . Patient factors affecting Helicobacter pylori eradication with triple therapy . Am J Gastroenterol . 1993;88:505–509
  27. O’Connor HJ , Kanduru C , Bhutta AS , et al.   Effect of Helicobacter pylori eradication on peptic ulcer healing . Postgrad Med J . 1995;71:90–93
  28. Fallone CA , Barkun AN , Friedman G , et al.   Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? . Am J Gastroenterol . 2000;95:914–920
  29. Gisbert JP , Gonzalez L , Calvet X , et al.   Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole (a meta-analysis of eradication of Helicobacter pylori) . Aliment Pharmacol Ther . 2000;14:1319–1328
  30. Kaushik SP , Vu C . Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin (testing an ideal regimen in a multicultural south east Asian population and examining factors potentially influencing eradication) . Aust N Z J Med . 2000;30:231–235
  31. Baena JM , Lopez C , Hidalgo A , et al.   Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week . Eur J Gastroenterol Hepatol . 2002;14:291–296
  32. Queiroz DM , Dani R , Silva LD , et al.   Factors associated with treatment failure of Helicobacter pylori infection in a developing country . J Clin Gastroenterol . 2002;35:315–320
  33. Mantzaris GJ , Petraki K , Archavlis E , et al.   Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection (a 24-month follow-up study) . Eur J Gastroenterol Hepatol . 2002;14:1237–1243
  34. Wu CJ , Hsu PI , Lo GH , et al.   Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection . J Chin Med Assoc . 2004;67:161–167
  35. Endoh K , Kauffman GL , Leung FW . Mechanism of aggravation of mucosal injury by intravenous nicotine in rat stomach . Am J Physiol . 1991;261:G1037–G1042
  36. Holm L , Perry MA . Role of blood flow in gastric acid secretion . Am J Physiol . 1988;254:G281–G293
  37. Parente F , Lazzaroni M , Sangaletti O , et al.   Cigarette smoking, gastric acid secretion, and serum pepsinogen I concentrations in duodenal ulcer patients . Gut . 1985;26:1327–1332
  38. Labenz J , Stolte M , Blum AL , et al.   Intragastric acidity as a predictor of the success of Helicobacter pylori eradication (a study in peptic ulcer patients with omeprazole and amoxicillin) . Gut . 1995;37:39–43
  39. van der Weide J , Steijns LS . Cytochrome P450 enzyme system (genetic polymorphisms and impact on clinical pharmacology) . Ann Clin Biochem . 1999;36:722–729
  40. Zevin S , Benowitz NL . Drug interactions with tobacco smoking. An update . Clin Pharmacokinet . 1999;36:425–438
  41. Villard PH , Seree EM , Re JL , et al.   Effects of tobacco smoke on the gene expression of the Cyp1a, Cyp2b, Cyp2e, and Cyp3a subfamilies in mouse liver and lung (relation to single strand breaks of DNA) . Toxicol Appl Pharmacol . 1998;148:195–204
  42. Furuta T , Ohashi K , Kamata T , et al.   Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer . Ann Intern Med . 1998;129:1027–1030
  43. Sagar M , Tybring G , Dahl ML , et al.   Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism . Gastroenterology . 2000;119:670–676
  44. Degoulet P , Menard J , Vu HA , et al.   Factors predictive of attendance at clinic and blood pressure control in hypertensive patients . Br Med J . 1983;287:88–93 (Clin Res Ed)
  45. Konturek SJ , Bielanski W , Plonka M , et al.   Helicobacter pylori, non-steroidal anti-inflammatory drugs and smoking in risk pattern of gastroduodenal ulcers . Scand J Gastroenterol . 2003;38:923–930
  46. Hamajima N , Matsuo K , Saito T , et al.   Interleukin 1 polymorphisms, lifestyle factors, and Helicobacter pylori infection . Jpn J Cancer Res . 2001;92:383–389
  47. Nakamura M , Haruma K , Kamada T , et al.   Cigarette smoking promotes atrophic gastritis in Helicobacter pylori-positive subjects . Dig Dis Sci . 2002;47:675–681
  48. Endoh K , Leung FW . Effects of smoking and nicotine on the gastric mucosa (a review of clinical and experimental evidence) . Gastroenterology . 1994;107:864–878
  49. Matsuo K , Hamajima N , Ikehara Y , et al.   Smoking and polymorphisms of fucosyltransferase gene Le affect success of H. pylori eradication with lansoprazole, amoxicillin, and clarithromycin . Epidemiol Infect . 2003;130:227–233
  50. Lamouliatte H , Samoyeau R , De Mascarel A , Megraud F . Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia . Aliment Pharmacol Ther . 1999;13:1523–1530
  51. Azuma T . Helicobacter pylori CagA protein variation associated with gastric cancer in Asia . J Gastroenterol . 2004;39:97–103

 This work was supported in part by a Grant-in-Aid for Cancer Research (17-1) from the Ministry of Health, Labour and Welfare, Tokyo, Japan.

PII: S0002-9343(05)00949-6

doi: 10.1016/j.amjmed.2005.10.003

The American Journal of Medicine
Volume 119, Issue 3 , Pages 217-224 , March 2006

Article Tools

* Image Usage & Resolution